Company Filing History:
Years Active: 2017
Title: Lili Tian: Innovator in Antidiabetic Compounds
Introduction
Lili Tian is a prominent inventor based in Shanghai, China. She has made significant contributions to the field of pharmaceuticals, particularly in the development of antidiabetic compounds. Her work focuses on innovative solutions for managing Type 2 diabetes mellitus and related conditions.
Latest Patents
Lili Tian holds a patent for "Antidiabetic substituted heteroaryl compounds." This invention relates to a compound represented by a specific formula and its pharmaceutically acceptable salts. The compounds are identified as agonists of G-protein coupled receptor 40 (GPR40) and are potentially useful in treating, preventing, and suppressing diseases mediated by this receptor. The compounds may aid in the treatment of Type 2 diabetes mellitus and associated conditions, including obesity and various lipid disorders.
Career Highlights
Lili Tian is currently employed at Merck Sharp & Dohme Corporation, where she continues her research and development efforts. Her work has garnered attention for its potential impact on diabetes treatment and management.
Collaborations
Lili collaborates with notable colleagues, including William K Hagmann and Bing Li. These partnerships enhance her research capabilities and contribute to the advancement of her innovative projects.
Conclusion
Lili Tian's contributions to the field of antidiabetic compounds highlight her role as a leading inventor in pharmaceutical innovation. Her work promises to improve the lives of those affected by diabetes and related health issues.